Total Payments
$880,329
2024 Payments
$151,091
Companies
11
Transactions
589
Medicare Patients
2,285
Medicare Billing
$430,411
Payment Breakdown by Category
Other$626,328 (71.1%)
Consulting$123,370 (14.0%)
Travel$104,539 (11.9%)
Food & Beverage$13,954 (1.6%)
Research$12,129 (1.4%)
Education$8.45 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $626,328 | 189 | 71.1% |
| Consulting Fee | $123,370 | 36 | 14.0% |
| Travel and Lodging | $104,539 | 165 | 11.9% |
| Food and Beverage | $13,954 | 190 | 1.6% |
| Unspecified | $12,129 | 8 | 1.4% |
| Education | $8.45 | 1 | 0.0% |
Payments by Type
General
$868,200
581 transactions
Research
$12,129
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $268,415 | 128 | $0 (2022) |
| ABBVIE INC. | $171,863 | 139 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $163,033 | 90 | $0 (2024) |
| Janssen Biotech, Inc. | $112,003 | 83 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $102,040 | 75 | $0 (2022) |
| PFIZER INC. | $26,576 | 44 | $0 (2024) |
| Takeda Pharmaceuticals International, Inc. | $24,914 | 9 | $0 (2019) |
| Janssen Global Services, LLC | $6,637 | 8 | $0 (2017) |
| Celgene Corporation | $4,252 | 10 | $0 (2024) |
| Eli Lilly and Company | $548.73 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151,091 | 115 | ABBVIE INC. ($61,841) |
| 2023 | $207,169 | 146 | E.R. Squibb & Sons, L.L.C. ($98,131) |
| 2022 | $135,840 | 93 | Janssen Scientific Affairs, LLC ($60,022) |
| 2021 | $77,377 | 43 | Takeda Pharmaceuticals U.S.A., Inc. ($40,218) |
| 2020 | $40,580 | 21 | Takeda Pharmaceuticals U.S.A., Inc. ($21,248) |
| 2019 | $95,490 | 54 | Takeda Pharmaceuticals U.S.A., Inc. ($52,154) |
| 2018 | $135,277 | 75 | Takeda Pharmaceuticals U.S.A., Inc. ($116,221) |
| 2017 | $37,506 | 42 | Takeda Pharmaceuticals U.S.A., Inc. ($10,445) |
All Payment Transactions
589 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| 12/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $647.72 | General |
| 12/04/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $89.57 | General |
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $839.74 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Immunology | ||||||
| 11/30/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $47.62 | General |
| Category: LIVER DISEASE | ||||||
| 11/27/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| 11/27/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| 11/27/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $653.23 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $34.52 | General |
| Category: Immunology | ||||||
| 11/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $147.76 | General |
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,125.00 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $653.23 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $639.20 | General |
| 11/13/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $113.36 | General |
| 11/12/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $486.48 | General |
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,104.50 | General |
| 11/07/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $486.48 | General |
| 11/07/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $126.29 | General |
| 11/04/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| INFLAMIMMUNO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $11,580 | 6 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $522.53 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $26.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 513 | 4,102 | $582,745 | $66,831 |
| 2022 | 13 | 614 | 5,580 | $559,270 | $86,630 |
| 2021 | 15 | 658 | 7,791 | $977,915 | $162,567 |
| 2020 | 12 | 500 | 6,271 | $659,965 | $114,384 |
Total Patients
2,285
Total Services
23,744
Medicare Billing
$430,411
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 168 | 311 | $132,175 | $25,157 | 19.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 76 | 78 | $218,790 | $12,608 | 5.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 85 | $36,125 | $6,963 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 30 | 35 | $19,250 | $4,303 | 22.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 37 | 37 | $19,425 | $4,106 | 21.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 13 | 32 | $18,080 | $3,935 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 35 | $19,250 | $3,748 | 19.5% |
| 44361 | Biopsy of small bowel (except ileum) using an endoscope | Facility | 2023 | 33 | 34 | $63,240 | $2,789 | 4.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $39,235 | $1,411 | 3.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 18 | 19 | $5,700 | $1,144 | 20.1% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 11 | 3,400 | $3,400 | $525.72 | 15.5% |
| 91065 | Measurement of hydrogen in breath to test for stomach and bowel symptoms | Facility | 2023 | 17 | 17 | $8,075 | $141.60 | 1.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 170 | 304 | $116,195 | $32,590 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 78 | 113 | $55,595 | $16,471 | 29.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 73 | 75 | $210,375 | $12,212 | 5.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 12 | 48 | $27,120 | $6,045 | 22.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 31 | 31 | $16,275 | $4,381 | 26.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $11,550 | $3,246 | 28.1% |
| 44361 | Biopsy of small bowel (except ileum) using an endoscope | Facility | 2022 | 32 | 33 | $61,380 | $2,595 | 4.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 25 | 25 | $10,625 | $2,136 | 20.1% |
| 91065 | Measurement of hydrogen in breath to test for stomach and bowel symptoms | Office | 2022 | 23 | 23 | $10,925 | $2,000 | 18.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 12 | 23 | $5,980 | $1,513 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 15 | $3,590 | $1,150 | 32.0% |
| 45331 | Biopsy of lower large bowel using a flexible endoscope | Facility | 2022 | 14 | 19 | $19,570 | $1,065 | 5.4% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2022 | 13 | 4,700 | $4,700 | $795.86 | 16.9% |
About Dr. Ellen Scherl, MD
Dr. Ellen Scherl, MD is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912024373.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ellen Scherl, MD has received a total of $880,329 in payments from pharmaceutical and medical device companies, with $151,091 received in 2024. These payments were reported across 589 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($626,328).
As a Medicare-enrolled provider, Scherl has provided services to 2,285 Medicare beneficiaries, totaling 23,744 services with total Medicare billing of $430,411. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 03/23/2007
- Last Updated 12/09/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1912024373
Products in Payments
- STELARA (Biological) $150,801
- Entyvio (Biological) $147,038
- ENTYVIO (Biological) $76,677
- TREMFYA (Drug) $44,659
- XELJANZ (Drug) $11,085
- SIMPONI (Biological) $8,099
- REMICADE (Biological) $7,528
- SKYRIZI (Biological) $6,175
- ZEPOSIA (Drug) $3,952
- RINVOQ (Biological) $1,667
- ORENCIA (Biological) $1,500
- VELSIPITY (Drug) $102.34
- CREON (Drug) $84.98
- LINZESS (Drug) $62.31
- RESMETIROM (Drug) $47.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554
Dr. Seth Gross, M.d, M.D
Gastroenterology — Payments: $746,602
Gastroenterology $746,602